Cargando…

BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer

Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indet...

Descripción completa

Detalles Bibliográficos
Autores principales: Monti, Eleonora, Bovero, Michela, Mortara, Lorenzo, Pera, Giorgia, Zupo, Simonetta, Gugiatti, Elena, Dono, Mariella, Massa, Barbara, Ansaldo, Gian Luca, Massimo, Giusti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674605/
https://www.ncbi.nlm.nih.gov/pubmed/26693224
http://dx.doi.org/10.1155/2015/138734
_version_ 1782404923083718656
author Monti, Eleonora
Bovero, Michela
Mortara, Lorenzo
Pera, Giorgia
Zupo, Simonetta
Gugiatti, Elena
Dono, Mariella
Massa, Barbara
Ansaldo, Gian Luca
Massimo, Giusti
author_facet Monti, Eleonora
Bovero, Michela
Mortara, Lorenzo
Pera, Giorgia
Zupo, Simonetta
Gugiatti, Elena
Dono, Mariella
Massa, Barbara
Ansaldo, Gian Luca
Massimo, Giusti
author_sort Monti, Eleonora
collection PubMed
description Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56/70 patients. The mutation was BRAF V600E in 12/56 cases (21%) and BRAF K601E in 2/56 (4%). Of the BRAF mutated samples on cytological diagnosis (14/56 cases), 2/14 cases (14%) were benign on final histology and 12/14 (86%) were malignant. All BRAF-mutated cases on cytology that were found to be benign on histological examination carried the K601E mutation. Of the nonmutated BRAF cases (42/56, 75%) which were later found to be malignant on definitive histology, 5 cases were follicular carcinomas (36%), 3 cases were incidentally found to be papillary microcarcinomas (22%), 2 were cases papillary carcinomas (14%), 1 was case follicular variant of papillary carcinoma (7%), 1 was case medullary carcinoma (7%), 1 case was Hurtle cell tumor (7%), and 1 case was combined cell carcinoma and papillary oncocytic carcinoma (7%). Conclusions. The presence of the BRAF V600E mutation may suggest a more aggressive surgical approach. BRAF K601E mutation did not correlate with malignancy indexes.
format Online
Article
Text
id pubmed-4674605
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-46746052015-12-21 BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer Monti, Eleonora Bovero, Michela Mortara, Lorenzo Pera, Giorgia Zupo, Simonetta Gugiatti, Elena Dono, Mariella Massa, Barbara Ansaldo, Gian Luca Massimo, Giusti Int J Endocrinol Research Article Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56/70 patients. The mutation was BRAF V600E in 12/56 cases (21%) and BRAF K601E in 2/56 (4%). Of the BRAF mutated samples on cytological diagnosis (14/56 cases), 2/14 cases (14%) were benign on final histology and 12/14 (86%) were malignant. All BRAF-mutated cases on cytology that were found to be benign on histological examination carried the K601E mutation. Of the nonmutated BRAF cases (42/56, 75%) which were later found to be malignant on definitive histology, 5 cases were follicular carcinomas (36%), 3 cases were incidentally found to be papillary microcarcinomas (22%), 2 were cases papillary carcinomas (14%), 1 was case follicular variant of papillary carcinoma (7%), 1 was case medullary carcinoma (7%), 1 case was Hurtle cell tumor (7%), and 1 case was combined cell carcinoma and papillary oncocytic carcinoma (7%). Conclusions. The presence of the BRAF V600E mutation may suggest a more aggressive surgical approach. BRAF K601E mutation did not correlate with malignancy indexes. Hindawi Publishing Corporation 2015 2015-11-26 /pmc/articles/PMC4674605/ /pubmed/26693224 http://dx.doi.org/10.1155/2015/138734 Text en Copyright © 2015 Eleonora Monti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Monti, Eleonora
Bovero, Michela
Mortara, Lorenzo
Pera, Giorgia
Zupo, Simonetta
Gugiatti, Elena
Dono, Mariella
Massa, Barbara
Ansaldo, Gian Luca
Massimo, Giusti
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
title BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
title_full BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
title_fullStr BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
title_full_unstemmed BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
title_short BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
title_sort braf mutations in an italian regional population: implications for the therapy of thyroid cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674605/
https://www.ncbi.nlm.nih.gov/pubmed/26693224
http://dx.doi.org/10.1155/2015/138734
work_keys_str_mv AT montieleonora brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT boveromichela brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT mortaralorenzo brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT peragiorgia brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT zuposimonetta brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT gugiattielena brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT donomariella brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT massabarbara brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT ansaldogianluca brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer
AT massimogiusti brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer